Monitor for interim data readouts in 2H 2026, which could serve as a key catalyst for stock movement. Positive safety and biodistribution data could validate the Tb161 platform and boost confidence in the broader pipeline.
Price Chart
Executive Summary
Radiopharm Theranostics has dosed the first patient in its Phase 1 clinical trial of RAD 402, a novel radiopharmaceutical targeting KLK3 for advanced prostate cancer. The trial is designed to assess safety, dosing, and preliminary efficacy, with data from the first two dose levels expected in the second half of 2026.
Key Facts
- First patient dosed in Phase 1 trial of RAD 402 for advanced prostate cancer
- Trial identifier: NCT07259213
- Primary goals: determine safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D)
- Data from first two dose levels expected in 2H 2026
- RAD 402 is a monoclonal antibody targeting KLK3 (PSA gene) radiolabeled with Terbium-161
- Preclinical data show strong tumor targeting, minimal bone/marrow uptake, and hepatic clearance
- Company is listed on ASX (RAD) and NASDAQ (RADX)
Financial Impact
No direct financial impact disclosed; clinical milestone may improve investor sentiment and valuation expectations
Risk Factors
- Phase 1 trials carry high risk of safety or tolerability issues
- Preclinical results may not translate to humans
- Dilutive financing risk if additional capital is needed to fund development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-035160 |
| Document: ea028376501_ex99-1.htm | 0001213900-26-035160 |
| Document: 0001213900-26-035160-index-headers.html | 0001213900-26-035160 |
| Document: 0001213900-26-035160-index.html | 0001213900-26-035160 |
| Document: 0001213900-26-035160.txt | 0001213900-26-035160 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 20w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −52.50% | $0.006660 (−66.70%) |
May 6, 2026 24w ago | 3 | $0.0200 $0.0100 | ▼ −50.00% | ▼ −53.83% | $0.006660 (−66.70%) |
Apr 23, 2026 26w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −55.02% | $0.006660 (−66.70%) |
Apr 16, 2026 27w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −57.05% | $0.006660 (−66.70%) |
Apr 8, 2026 28w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −60.46% | $0.006660 (−66.70%) |
Apr 7, 2026 28w ago | 6-K | $0.0200 $0.0100 | ▼ −50.00% | ▼ −63.27% | $0.006660 (−66.70%) |
Apr 1, 2026 29w ago | 3 | $0.0200 $0.0100 | ▼ −50.00% | ▼ −64.16% | $0.006660 (−66.70%) |
Mar 27, 2026 30w ago | 6-K | $0.0200 $0.0200 | · 0.00% | ▼ −16.07% | $0.006660 (−66.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers